Therapy Areas: Cardiovascular
Horizon Discovery awards GS knockout CHO K1 Cell Line to NGM Bio to support research and development of biotherapeutics across therapeutic areas
22 January 2020 -

Gene editing company Horizon Discovery Group plc (LSE:HZD) said on Tuesday that it has entered into an agreement to license its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line to NGM Biopharmaceuticals Inc (Nasdaq:NGM).

Based in South San Francisco, California, NGM is focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.

According to Horizon, its proprietary GS knockout CHO K1 cell line and protocols facilitate the development of stable cell lines for the expression of antibodies and other recombinant proteins.

To enable companies to move from the DNA sequence of their potential biotherapeutic to clinical manufacturing as simply and rapidly as possible, Horizon's complete system includes the GS knockout CHO K1 cell line, a comprehensive package of supporting documentation as well as an expression vector supplied under license from DNATwoPointO Inc.

Login
Username:

Password: